Company Description
Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States.
The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors.
The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets.
Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.
Country | United States |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 62 |
CEO | Dr. Eric E. Poma Ph.D. |
Contact Details
Address: 9301 Amberglen Blvd, Suite 100 Austin, Texas 78729 United States | |
Phone | 512 896 1555 |
Website | mtem.com |
Stock Details
Ticker Symbol | MTEM |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001183765 |
CUSIP Number | 608550109 |
ISIN Number | US6085502085 |
Employer ID | 94-3409596 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Eric E. Poma Ph.D. | Chief Executive Officer, Chief Scientific Officer and Director |
Jason S Kim | President, Chief Financial Officer, Treasurer and Principal Accounting Officer |
Kristen Quigley B.A. | Chief Operating Officer |
Dr. Grace Kim | Chief Strategy Officer and Head of IR |
Dr. Joseph Phillips Ph.D. | Senior Vice President and Head of CMC Development |
Dr. Maurizio Voi M.D. | Chief Medical Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 3, 2024 | 8-K | Current Report |
May 15, 2024 | 10-Q | Quarterly Report |
May 15, 2024 | 8-K | Current Report |
May 3, 2024 | EFFECT | Notice of Effectiveness |
May 3, 2024 | 424B3 | Prospectus |
May 1, 2024 | UPLOAD | Filing |
Apr 29, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Apr 25, 2024 | S-3 | Registration statement under Securities Act of 1933 |
Apr 25, 2024 | 10-K/A | [Amend] Annual report |
Apr 12, 2024 | 8-K | Current Report |